Teva Pharmaceuticals Appeals to Federal Circuit to Secure Inhaler Patents in Supreme Court Bid

Teva Pharmaceuticals, an Israeli drugmaker, is currently seeking the Federal Circuit’s approval to maintain an injunction that prevents the removal of its inhaler patents from the U.S. Food and Drug Administration’s Orange Book. This maneuver is part of Teva’s efforts to appeal the case to the U.S. Supreme Court. The patents in question are pivotal to the company’s operations, and Teva is determined to explore all legal avenues to defend its interests. According to Law360, the company has initiated this legal step as part of broader strategies to secure its intellectual properties amid ongoing litigation. The outcome of this appeal could have significant implications for Teva’s strategies in the U.S. market.